GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bio Preventive Medicine 6810.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

20.80

+2.97%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bio Preventive Medicine

Its shares trade on Taipei Exchange under the ticker 6810.TWO. It has been listed since 30 August 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 2.6m and a net loss of TWD 99.8m. At that date it held total assets of TWD 425.2m and shareholders' equity of TWD 307.2m.

Bio Preventive Medicine Corp. is an clinical-staged biotech company, mainly focusing on early detection and prevention of diseases specialty of those high value added molecular diagnostic product. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2021-08-30. The main products are in vitro testing reagents, which are mainly used in the early detection and prevention of diabetes complications, chronic kidney diseases and other chronic diseases, and cancers. The firm operates in North America, Europe, Asia and South America markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Aug 2021

Leadership

Pay as last reported

  • Ms. Ziling ZengChairman of the Board, General Manager, since 2014
  • Yuhua ZengDeputy General Manager-Business Marketing
  • Zuxun GuoHead of Finance & Accounting
  • Tingkuan LinDirector
  • Changli XuDirector
  • Ms. Dah-Tsyr ChangIndependent Director
  • Mr. Qiongyu HuangIndependent Director
  • Mr. Fanquan ShiIndependent Director
  • Mr. Yau-Huei WeiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Clinical-staged biotech company with molecular diagnostic products for diabetes complications prevention.
  • Headquartered in Zhubei, Hsinchu, serving global markets including North America and Europe.
  • IPO listed on 30 August 2021, operating in multiple continents for chronic disease detection.

Weaknesses

  • Limited to in vitro testing reagents for chronic disease detection without expansion into other product segments.
  • Operates in North America, Europe, Asia, and South America but lacks specific market share data.
  • No mention of R&D investment or clinical trial progress beyond early stages.

Opportunities

  • Growing global demand for early disease detection in chronic conditions like diabetes and cancer.
  • Expansion into new markets within Asia and South America for molecular diagnostic products.
  • Increased focus on preventive healthcare in the Health Care sector globally.

Threats

  • Competition from established biotech firms in molecular diagnostics without specified competitors.
  • Regulatory challenges in multiple countries for medical testing products.
  • Economic downturns affecting healthcare spending in North America and Europe markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.